mergers & acquisitions
General Business

Zoetis to Acquire Provider, Manufacturer of Livestock and Companion Animal Products

Zoetis Inc., a world-leading animal health company based in Parsippany, has entered into an agreement to acquire Jurox, a privately held company that develops, manufactures and markets a wide range of veterinary medicines for treating companion animals and livestock. Jurox’s operations are based in Australia, with additional regional offices and subsidiaries in New Zealand, U.S., Canada and the UK. Financial terms of the transaction are not being disclosed.

Once completed, the acquisition of Jurox will bring Zoetis a range of important products primed for greater global expansion; a valuable animal health portfolio, including Alfaxan®, a leading anaesthetic product for companion animals; and high-quality, local manufacturing operations in Australia, a critical region for growth. Australia is Zoetis’ fifth largest market, based on $207 million in revenue in 2020.

“Jurox’s portfolio plays to the strengths of our core business and will be a complementary fit with the solutions we deliver to veterinary professionals, livestock producers and pet owners,” said Zoetis CEO Kristin Peck. “We continue to look for investment opportunities where we can combine a terrific business with the strengths of Zoetis and enhance the combined value to our business and customers.

“With Zoetis’ global sales and regulatory expertise in more than 45 direct markets, we look forward to expanding the impact and reach of the entire Jurox portfolio.” Jurox manufactures and commercializes more than 150 products, including parasiticides, anti-infectives, anaesthesia, cardiology and reproduction for animals.”

“Jurox and Zoetis share similar beliefs about the important role animal health plays in the world, as well as the high standards we must keep to bring meaningful solutions to our customers,” said Jurox CEO John O’Brien. “We look forward to the future that Jurox and Zoetis can build together in Australia and around the world.”

The transaction is subject to customary closing conditions and the satisfaction of regulatory requirements. Zoetis expects to complete the acquisition in the first half of 2022. Upon closing, Jurox is expected to continue operations in its Rutherford, Australia, headquarters and manufacturing location.

To access more business news, visit NJB News Now.

Related Articles: